Crystagen
Immune / GeneralAlso known as: Immune peptide complex
Mechanism
An oral peptide complex that supports both innate and adaptive immunity. It provides broader immune support than Vladonix (which is thymus-specific). Used as a general immune bioregulator in Khavinson's oral supplement line.
Technical detail
Peptide complex designed to support comprehensive immune function, targeting multiple immune cell types including natural killer cells, macrophages, and lymphocytes. Unlike Vladonix (thymus-specific), Crystagen contains peptides proposed to modulate gene expression across the immune system broadly — promoting NK cell cytotoxicity, macrophage phagocytic activity, and immunoglobulin production. In animal studies, improved resistance to experimental infections and normalized immune cell ratios after immunosuppression. Part of the Cytomax oral bioregulator series. Exact peptide composition proprietary.
Effects
**Immune System (Tier 3 — Russian Bioregulator Research):** Crystagen is a synthetic tripeptide (Glu-Asp-Gly) developed by Prof. Vladimir Khavinson as a thymus bioregulator. Part of the Khavinson "cytogen" series of short synthetic peptides designed to replicate the effects of organ-specific natural bioregulators. Proposed mechanism: epigenetic regulation of immune-related gene expression through interaction with specific DNA sequences in promoter regions of genes involved in T-cell differentiation and function. **T-Cell Modulation (Tier 3):** Claimed effects include normalization of T-cell subpopulations (CD4, CD8, CD16), enhancement of phagocytic activity, and restoration of cytokine balance. In Khavinson laboratory studies, crystagen upregulated expression of genes involved in immune cell differentiation and proliferation in cell culture models. **Aging/Immunosenescence (Tier 3):** As part of the Khavinson bioregulator approach, crystagen is used to address age-related decline in thymic function and T-cell output. Proposed to work at the epigenetic level — modifying histone acetylation and DNA methylation patterns in immune-related genes.
Practitioner Guide
**Standard Bioregulator Protocol:** - Available as oral capsule form (most common) — 10mg capsules - Dose: 1-2 capsules daily for 10-30 days - Cycle: repeat every 3-6 months - Can be combined with other Khavinson bioregulators (vladonix for thymus, ventfort for vessels, etc.) **Clinical Context:** - Crystagen is part of the Khavinson synthetic peptide bioregulator system — a uniquely Russian approach to medicine - Limited availability outside of Russia and Eastern Europe - No FDA or EMA approval; not recognized as a pharmaceutical in Western medicine - Practitioners who use it are typically within the bioregulator medicine specialty or Russian-trained integrative medicine **When Practitioners Use It:** - Age-related immune decline in patients 50+ - Post-illness immune recovery - Seasonal immune support (fall/winter) - As a more accessible alternative to injectable thymalin (oral vs. injection) **Honest Assessment:** - The evidence base is limited to Khavinson laboratory publications and Russian clinical literature - Western peer review of claims is minimal - For practitioners seeking immune peptide therapy with stronger evidence: thymosin alpha-1 is the better-supported option - Crystagen may have value as a low-risk oral immune support, but should not replace evidence-based treatments for serious immune conditions
Research Summary
**Tier 2 — Russian Published Research:** - Khavinson lab publications: in vitro studies showing crystagen (Glu-Asp-Gly) binds to specific DNA sequences and modulates gene expression in lymphocyte cultures - Russian clinical studies: small trials (n=20-50) in elderly patients showing normalization of immune markers after 10-day oral crystagen courses - Published in Russian journals (Bulletin of Experimental Biology and Medicine, Advances in Gerontology) **Tier 3 — Emerging/Limited Western Evidence:** - No Western peer-reviewed clinical trials - Mechanism of action (short peptide interacting directly with DNA promoter regions) is theoretically plausible but incompletely validated by independent laboratories - Part of the broader "peptide bioregulation" theory that short peptides can have tissue-specific epigenetic effects — an area of legitimate scientific interest but limited independent replication - No pharmacokinetic studies confirming oral bioavailability of the intact tripeptide (di/tripeptides can be absorbed via PepT1 transporter — biologically plausible)